HRTX · Heron Therapeutics, Inc. /De/
$0.36
+0.01 (+2.96%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$55.85M
Shares
189.85M
Volume · Oct 5
1.53M
Avg daily vol (3M)
2.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.35
Open$0.36
Day$0.34–0.41
52W close$0.27–1.49
Avg vol 30d2.3M
Short int43.4M · 22.8% float · 27.8d
Short vol41%
Last earningsAug 10, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$151.18M
Trailing 12 months
Net income (TTM)
−$34.05M
Trailing 12 months
Revenue growth YoY
+1.3%
Year over year
Operating margin
-7.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$20.72M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+23.6%
Year over year · more shares
Price change (1Y)
-73.3%
Trailing year
Short interest
22.8%
Latest settlement · 27.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26
TL;DR. Heron reported Q2 net revenue of $37.7 million with strong acute care growth (ZYNRELEF +35% and APONVIE +74% year-over-year), but withdrew its full-year 2026 guidance following a June court decision on CINVANTI patents that threatens potential generic entry. The company reset its Hercules credit facility, reducing principal by up to $17.5 million and resetting covenants through 2027, and is evaluating strategic alternatives.
Bullish
- + Acute care franchise delivered $15.3 million, up 43.9% year-over-year
- + ZYNRELEF net revenue grew 35% year-over-year to $11.1 million
- + APONVIE net revenue grew 74% year-over-year to $4.2 million with 23% NK1 segment share
- + Hercules credit facility amended with covenants reset through 2027 and up to $17.5 million principal reduction
- + Adjusted EBITDA improved to $3.2 million from $2.2 million year-over-year
Bearish
- − Withdrew full-year 2026 guidance of $173-183 million net product sales and $10-20 million adjusted EBITDA
- − CINVANTI declined 9.7% year-over-year to $21.8 million due to branded competition and faces potential generic entry
- − ZYNRELEF Q2 performance came in below company expectations
- − Net loss widened to $5.5 million from $2.4 million year-over-year
- − Pro forma cash falls to approximately $24.3 million after September payment from $42.7 million
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−56%
below
Price vs 50-day avg
−3%
below
RSI (14)
57
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−62%
trailing
YTD return
−73%
this year
Relative strength
−74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
22.85% of float · ▼ -3.3% MoM · 27.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
164 holders — mid 3-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
73%
expanding
EPS growth
−33%
Y/Y
Free cash flow
$-27.9M
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Net product sales
· 2026
$173M – $183M
prior FY $154.9M
midpoint +14.9% Y/Y
Adjusted EBITDA
· 2026
Non-GAAP
$10M – $20M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−56%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
22.85% of float · ▼ -3.3% MoM · 27.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
164 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 6%
Range high $1
vs 200-day avg -56%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.52M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HRTX
this stock
Heron Therapeutics, Inc. /De/
|
$55.85M | -73.3% | +7.4% | — | 22.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Congressional Trades
Sell
Member
Ashley Hinson Arenholz
- Amount
- $1.0K–$15.0K
- Traded
- Mar 31, 2021
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HRTX | +18.2% | +5.3% | -61.8% | +10.9% | -73.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +18.4% | +5.8% | -74.0% | +10.0% | -86.1% |